Washington, D.C. 20549

Form 6-K


For the month of November 2018

Commission File Number: 333-219066

Clementia Pharmaceuticals Inc.
(Translation of registrant's name into English)

4150 St Catherine Street West, Suite 550
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. 

The information contained in this Report (including the exhibits hereto) is hereby incorporated by reference into Clementia Pharmaceuticals Inc.’s Registration Statement on Form F-3 (File No. 333-227726).

On November 7, 2018, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated November 7, 2018


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

        Clementia Pharmaceuticals Inc.    
Date: November 7, 2018       /s/ Steve Forte    
    Steve Forte
    Chief Financial Officer


Clementia Reports Third Quarter 2018 Operating Results and Pipeline Updates

Recent FDA Meeting Identifies Path Towards NDA Submission in the Second Half of 2019

Financing Raises $75 million to Support a Potential Commercial Launch

MONTREAL, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today reported financial results for the third quarter ended September 30, 2018 and provided an update on recent progress and upcoming milestones.

“This has been a transformational year for Clementia, with our lead product candidate, palovarotene, advancing towards an NDA submission in the second half of 2019, which if approved, could be the first available treatment indicated for FOP,” said Clarissa Desjardins, Ph.D., president and chief executive officer of Clementia. “Over the next 12 months we also expect to complete enrollment in our MO-Ped Trial, the first-ever clinical trial to test a potential treatment for Multiple Osteochondromas (MO), to reach the first two interim analyses from our MOVE Trial, and to report the results of our Phase 1 study of our palovarotene eye drop formulation for dry eye disease. With our recently completed financing we now have the resources to bring palovarotene to market upon approval, while advancing our other clinical programs to key value inflection points.”

Recent Pipeline Progress and Upcoming Milestones

Recent Business Updates

Third Quarter 2018 Financial Results (all amounts are presented in U.S. dollars)

About Clementia Pharmaceuticals Inc.
Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders and other diseases with high medical need. The company is preparing for a 2019 NDA submission to the FDA to seek approval of its lead product candidate, palovarotene, a novel RARγ agonist, for the prevention of heterotopic ossification (HO) associated with flare up symptoms in patients with fibrodysplasia ossificans progressiva (FOP). The ongoing Phase 3 MOVE Trial is evaluating an additional dosing regimen of palovarotene which includes a chronic 5 mg daily dose in addition to the episodic 20/10 mg dosing regimen at the time of a flare-up. Palovarotene is also in a Phase 2 trial, the MO-Ped Trial, for the treatment of multiple osteochondromas (MO, also known as multiple hereditary exostoses, or MHE). In addition, Clementia has commenced a Phase 1 trial for an eye drop formulation of palovarotene for the potential treatment of dry eye disease and is also investigating other conditions that may benefit from RARγ therapy. For more information, please visit www.clementiapharma.com and connect with us on Twitter @ClementiaPharma.

Cautionary Note Regarding Forward-Looking Statements
This press release may include “forward-looking statements” within the meaning of the applicable securities laws, including with respect to the proposed timing of submission of the NDA for palovarotene. Each forward-looking statement contained in this press release is subject to known and unknown risks and uncertainties and other unknown factors that could cause actual results to differ materially from historical results and those expressed or implied by such statement. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “will,” or “plans” to be uncertain and forward-looking. Applicable risks and uncertainties include, among others, the company’s ability to successfully complete in a timely manner the studies required to be completed in order to submit the NDA; the company’s ability to generate revenue and become profitable; the risks related to its heavy reliance on palovarotene, its only current product candidate; the risks associated with the development of palovarotene and any future product candidate, including the demonstration of efficacy and safety; its dependence on licensed intellectual property, including the ability to source and maintain licenses from third-party owners; as well as the risks identified under the heading “Risk Factors” in the company’s Annual Report on Form 20-F filed with the Securities and Exchange Commission (“SEC”), as well as the other information it files with the SEC or on SEDAR. Clementia cautions investors not to rely on the forward-looking statements contained in this press release when making an investment decision in its securities. Investors are encouraged to read the company’s filings with the SEC or on SEDAR, available at www.sec.gov or www.sedar.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this press release, and the company undertakes no obligation to update or revise any of these statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor/Media Contact:
Joseph Walewicz
Clementia Pharmaceuticals Inc.

Alicia Davis
THRUST Strategic Communications
+1-910- 620-3302

Clementia Pharmaceuticals Inc.
Interim Condensed Consolidated Statements of Financial Position (unaudited)
As at
(in US dollars)
September 30, 2018   December 31, 2017
Current assets    
Cash   $12,056,908   $36,230,343
Short-term investments 70,000,000   30,000,000
Interest receivable 181,407   575,499
Sales tax and other receivables 168,459   94,497
Income tax and tax credits receivable 1,044,285   977,901
Prepaid expenses 4,609,489   3,023,125
Total current assets 88,060,548   70,901,365
Non-current assets    
Long-term investments 25,000,000   75,000,000
Long-term prepaid expenses 733,058   775,757
Property and equipment 18,987   33,084
Intangible assets 1,570,486   1,715,192
Total non-current assets 27,322,531   77,524,033
Total assets $115,383,079   $148,425,398
Current liabilities    
Accounts payable and accrued liabilities $8,792,166   $6,718,666
Total liabilities 8,792,166   6,718,666
Common shares 230,659,692   230,659,692
Contributed surplus 6,319,484   2,659,348
Deficit (130,388,263 ) (91,612,308)
Total equity 106,590,913   141,706,732
Total equity and liabilities $115,383,079   $148,425,398

Clementia Pharmaceuticals Inc.
Interim Condensed Consolidated Statements of Net Loss and Comprehensive Loss (unaudited)
  Three-month periods ended  September 30,
  Nine-month periods ended  September 30,
(in US dollars) 2018    2017   2018    2017  
Research and development expenses $10,691,399   $7,073,872   $29,124,117   $16,813,902  
Investment tax credits
(363,232 ) (91,484 ) (718,187 ) (211,524 )
    10,328,167   6,982,388     28,405,930   16,602,378  
General and administrative expenses 4,447,953   2,816,980   11,204,722   6,878,786  
Interest income (531,479 ) (316,081 ) (1,622,109 ) (503,915 )
Financial expenses 3,776   29,415,957   71,541   80,440,739  
Net loss before income taxes
14,248,417   38,899,244   38,060,084   103,417,988  
Income tax expense 528,694   106,310   715,871   248,338  
Net loss and comprehensive loss ($ 14,777,111 ) ($39,005,554 ) ($ 38,775,955 ) ($103,666,326 )
Basic and diluted loss per share
($0.46 ) ($1.83 ) ($1.22 ) ($11.81 )
Weighted average number of outstanding basic and diluted shares 31,717,584   21,317,604   31,717,584   8,778,602  

Clementia Pharmaceuticals Inc.
Interim Condensed Consolidated Statements of Cash Flows (unaudited)
  Three-month periods ended  September 30,
  Nine-month periods ended  September 30,
(in US dollars) 2018   2017   2018   2017  
Operating activities        
Net loss ($14,777,111 ) ($39,005,554 ) ($38,775,955 ) ($103,666,326 )
Adjusting items        
Interest income recognized in net loss (531,479 ) (316,081 ) (1,622,109 ) (503,915 )
Depreciation of property and equipment 4,733   6,063   14,097   19,855  
Amortization of intangible assets 48,765   48,673   144,706   130,718  
Transaction costs recognized in net loss -   -   -   35,175  
Embedded derivative loss recognized in net loss -   29,007,078   -   77,902,663  
Accretion of preferred shares -   393,425   -   2,479,161  
Share-based compensation 1,656,408   795,806   3,660,136   1,478,082  
Net foreign exchange gain (16,729 ) (32,634 ) 37,884   (48,026 )
Income tax expense recognized in net loss 528,694   106,310   715,871   248,338  
Income taxes paid (4,375 ) (42,500 ) (64,068 ) (130,589 )
Tax credits (248,641 ) -   (409,638 ) -  
Net changes in working capital        
Sales tax and other receivables (95,768 ) (49,860 ) (75,846 ) (74,884 )
Investment tax credits receivable (114,591 ) (91,484 ) (308,549 ) (211,524 )
Deferred financing costs (18,165 ) 275,784   (18,165 ) -  
Prepaid expenses 583,103   (3,727,642 ) (1,525,500 ) (3,807,706 )
Accounts payable and accrued liabilities 330,564   457,938   2,078,396   1,835,789  
Net operating cash flows (12,654,592 ) (12,174,678 ) (36,148,740 ) (24,313,189 )
Investing activities        
Interest income received 1,752,656   184,040   2,016,201   551,412  
Acquisition of short and long-term investments (15,000,000 ) (109,000,000 ) (20,000,000 ) (134,000,000 )
Maturity of short-term investments 25,000,000   19,000,000   30,000,000   49,000,000  
Acquisition of property and equipment -   (4,194 ) -   (17,022 )
Acquisition of intellectual property -   -   -   (1,000,000 )
Net investing cash flows
11,752,656   (89,820,154 ) 12,016,201   (85,465,610 )
Financing activities        
Issuance of common shares -   -   -   31,588  
Issuance of common shares upon public offering -   137,865,000   -   137,865,000  
Share issuance costs -   (10,236,593 ) -   (10,236,593 )
Issuance of preferred shares -   -   -   10,000,080  
Issue costs of preferred shares -   -   -   (129,520 )
Net financing cash flows -   127,628,407   -   137,530,555  
Net (decrease) increase in cash
(901,936 ) 25,633,575   (24,132,539 ) 27,751,756  
Cash at beginning of period 12,937,235   11,584,221   36,230,343   9,434,495  
Effect of exchange rate fluctuations on cash held 21,609   20,400   (40,896 ) 51,945  
Cash at end of period 12,056,908   $37,238,196   12,056,908   $37,238,196